Moderna MRNA is experiencing a mix of positives and negatives. On the upside, Moderna’s Q3 earnings weren't as bleak as anticipated, with the company showing resilience through sharp cost cuts, a tightening of its sales forecast and a strong Q3 revenue, particularly from COVID vaccine sales. The company also made strides in pipeline progress, despite weakening demand for its COVID-19 vaccine. Its experimental flu vaccine has shown promise in a trial, even as it invests further in cancer therapies. Meanwhile, Moderna’s mRNA vaccines are believed to help some cancer patients fight tumors. These developments have helped their stock see occasional upswings.
Nevertheless, the company's COVID-19 vaccine sales have been falling, and constitute a bulk of their revenue. Moreover, Moderna received a blow after its CMV Vaccine Candidate performed poorly in a late-stage trial and company lowered its R&D spending. There’s increased scrutiny on its vaccine due to safety concerns affecting its valuation. Also, the cancellation of a U.S. contract to develop a bird flu vaccine and Moderna withdrawing its application for a Flu/COVID-19 combo vaccine weren’t favorable either. Furthermore, RFK Jr ended support for mRNA vaccine development, affecting many firms including Moderna.
Moderna MRNA News Analytics from Mon, 24 Mar 2025 07:00:00 GMT to Sat, 08 Nov 2025 18:46:03 GMT -
Rating 0
- Innovation 2
- Information 3
- Rumor -4
